Skip to main content
. 2019 Oct 31;15(10):e1008057. doi: 10.1371/journal.ppat.1008057

Fig 7. Inhibition of endogenous interferon responses enhances VA1 infection.

Fig 7

A) Timecourse of VA-1 infection in the presence or absence of ruxolitinib. C68 HIE was treated with ruxolitinib (5 μM) for 12 hrs before VA1 (MOI = 1) infection. Viral genome copies were determined by RT-qPCR from extracted RNA at days 0, 1, 2 and 3 post infection. B) The effect of ruxolitinib (5 μM) treatment on VA1 infection of selected HIE derived from different human intestinal segments was determined at 3 dpi by RT-qPCR. Data are from ≥ 3 experiments; error = mean ± SD. Abbreviations: D = duodenum, I = ileum, C = colon. The numbers indicate patient identifiers. NS = not significant, ***P<0.001.